1	Severity of Omicron (B	.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among
2	hospitalised adults: a pros	pective cohort study in Bristol, United Kingdom
3	Dr Catherine Hyams PhD ⁺	^{1,6} , Dr Robert Challen PhD ^{†2,6} , Dr Robin Marlow PhD ¹ , Dr Jennifer
4	Nguyen ScD MPH ³ , Dr Eliz	zabeth Begier MD MPH ³ , Dr Jo Southern PhD ³ , Ms Jade King MSc ⁴ ,
5	Ms Anna Morley MSc ⁵ , M	s Jane Kinney BSc ⁶ , Ms Madeleine Clout BSc ⁶ , Dr Jennifer Oliver
6	PhD ⁶ , Dr Sharon Gray MS	³ , Dr Gillian Ellsbury MD ³ , Prof Nick Maskell MD ⁵ , Dr Luis Jodar
7	PhD ³ , Dr Bradford Gessner	PhD ³ , Dr John McLaughlin PhD ³ , Dr Leon Danon PhD ^{2,6} , Professor
8	Adam Finn PhD FRCP ^{1,6} (C	corresponding Author), On behalf of The Avon CAP Research Group
9	† These authors contributed	equally, and should be considered co-first authors
10	1 Population Health Science	es, University of Bristol, Bristol, UK
11	2 Engineering Mathematics	, University of Bristol, UK
12	3 Vaccines Medical Develo	pment, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA,
13	USA	
14	4 Vaccine and Testing Team	n, Clinical Research Facility, UHBW NHS Trust, Bristol, UK
15	5 Academic Respiratory Un	it, University of Bristol, Southmead Hospital, Bristol, UK
16	6 Bristol Vaccine Centre, P	opulation Health Sciences, University of Bristol, Bristol, UK
17 18 19 20 21 22 23 24	Corresponding Author:	Professor Adam Finn, PhD Bristol Vaccine Centre, University of Bristol Level 6, UHB Education and Research Centre Upper Maudlin Street Bristol BS2 8AE United Kingdom +44(0)117 342 0160 adam.finn@bristol.ac.uk
25 26	Keywords: COVID-19,	SARS-CoV-2, respiratory infection, vaccination

28 ABSTRACT (250/250)

29 Background

30 There is an urgent public health need to evaluate disease severity in adults hospitalised with

- 31 Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist assessing
- 32 severity of disease in adults hospitalised with Omicron SARS-CoV-2 infections, and to what
- 33 extent patient-factors, including vaccination, age, frailty and pre-existing disease, affect variant-
- 34 dependent disease severity.

35 Methods

36 A prospective cohort study of adults (≥ 18 years of age) hospitalised with acute lower respiratory

37 tract disease at acute care hospitals in Bristol, UK conducted over 10-months. Delta or Omicron

38 SARS-CoV-2 infection was defined by positive SARS-CoV-2 PCR and variant identification or

39 inferred by dominant circulating variant. We constructed adjusted regression analyses to assess

40 disease severity using three different measures: $FiO_2 > 28\%$ (fraction inspired oxygen), World

41 Health Organization (WHO) outcome score >5 (assessing need for ventilatory support), and

42 hospital length of stay (LOS) >3 days following admission for Omicron or Delta infection.

43 **Findings**

44 Independent of other variables, including vaccination, Omicron variant infection in hospitalised

45 adults was associated with lower severity than Delta. Risk reductions were 58%, 67%, and 16%

- 46 for supplementary oxygen with >28% FiO₂ [Relative Risk (RR)=0.42 (95% CI: 0.34-0.52),
- 47 P < 0.001], WHO outcome score >5 [RR=0.33 (95%CI: 0.21-0.50), P < 0.001], and to have had a

48 LOS>3 days [RR=0.84 (95%CI: 0.76-0.92), P<0.001]. Younger age and vaccination with two or

- 49 three doses were also independently associated with lower COVID-19 severity.
- 50 Interpretation

51	We provide reassuring evidence that Omicron infection results in less serious adverse outcomes
52	than Delta in hospitalised patients. Despite lower severity relative to Delta, Omicron infection
53	still resulted in substantial patient and public health burden and an increased admission rate of
54	older patients with Omicron which counteracts some of the benefit arising from less severe
55	disease.
56	Funding
57	AvonCAD is an investigator lad project funded under a collaborative agreement by Drizer

57 AvonCAP is an investigator-led project funded under a collaborative agreement by Pfizer.

59 **RESEARCH IN CONTEXT**

60 Evidence before this study

61 The burden of COVID-19 on hospital services is determined by the prevalence and severity of 62 SARS-CoV-2 variants, and modified by individual factors such as age, frailty and vaccination 63 status. Real world data suggest that vaccine effectiveness is lower and may wane faster over time 64 against symptomatic disease with Omicron (B.1.1.529) than with Delta (B.1.617.2) SARS-CoV-65 2 variant. However, numbers of hospitalisations as a case proportion during the Omicron wave have been considerably lower than previous waves. Several reports have compared the risk of 66 67 hospitalisation or severe disease based on SARS-CoV-2 variant, some suggesting that Omicron 68 is probably less severe than Delta in vaccinated and unvaccinated individuals.

69 Added value of this study

70 This study provides robust data assessing the relative severity of Delta and Omicron SARS-CoV-71 2 variants in patients admitted to hospital, including the first analysis assessing risk for any 72 positive pressure ventilatory support, as well as risk of supplementary oxygen requirement and 73 extended hospital admission, that may guide resource planning in hospitals. We found evidence 74 that infection with Omicron was associated with a milder clinical course following hospital 75 admission than that caused by Delta and that vaccination was independently associated with 76 lower in-hospital disease severity using these three separate severity measures. Specifically, 77 compared to Delta, Omicron-related hospitalizations were 58%, 67%, and 16% less likely to 78 require high flow oxygen >28% FiO₂, positive pressure ventilatory support or more critical care, 79 and to have a hospital stay lasting more than three days, respectively.

80 This study reports the considerable morbidity resulting from Omicron infection, with 18% of 81 Omicron admissions requiring oxygen supplementation $FiO_2 > 28\%$, 6% requiring positive 82 pressure ventilation, 62% needing hospitalization \geq four days, and 4% in-hospital mortality. In 83 determining the reduced requirement of increased oxygen requirement and total positive pressure 84 requirement, including non-invasive ventilation, this analysis should contribute to future hospital 85 care and service planning assessments.

86 Implications of all the available evidence

The risk of severe outcomes following SARS-CoV-2 infection is substantially lower for Omicron than for Delta, with greater reductions for more severe disease outcomes. Significant variation in risk occurs with age and vaccination status, with older and unvaccinated individuals remaining at particular risk of adverse outcome. These results highlight the importance of maintaining high levels of vaccine coverage in patient groups at risk of severe disease.

The impact of lower severity Omicron-related hospitalization must be balanced against increased transmissibility and overall higher numbers of infections with this variant and there remains a substantial patient and public health burden. The increased admission rate of older patients with Omicron counteracts some of the benefit arising from less severe disease. Despite the risk reduction in high level oxygen supplementation requirement and high dependency care with Omicron compared to earlier variants at the individual level, healthcare systems could still be overwhelmed.

99 INTRODUCTION

- 100 The emergence of SARS-CoV-2 has resulted in a global pandemic, with multiple variants
- 101 detected since the wild-type virus emerged. The Delta variant (B.1.617.2) was first detected in
- 102 India in March 2021, spread rapidly [1] and resulted in a sharp rise in SARS-CoV-2 cases in the
- 103 United Kingdom [2]. The Omicron (B.1.1.529) variant, first detected in South Africa in
- 104 November 2021, rapidly replaced Delta as the main circulating variant globally and resulted in a
- 105 fourth wave of SARS-CoV-2 infection in the UK. By 26th December 2021, 95% of UK SARS-
- 106 CoV-2 cases were estimated to be caused by Omicron [3].

107

108 SARS-CoV-2 variants may differ in their capacity to infect and transmit, susceptibility either to

109 vaccine- or infection-derived immunity and clinical phenotype including disease severity.

110 Laboratory data suggest that vaccine-induced neutralizing antibody activity is lower against

111 Delta [4,5] and Omicron variants [6,7] than against the Alpha variant and wild/prototype viral

112 strains. Real world data subsequently confirmed vaccine effectiveness is lower against

symptomatic disease with Omicron than with Delta and other prior variants [8,9], with protection

114 that may also wane faster over time [10-13]. However, numbers of hospitalisations as a case

115 proportion during the Omicron wave have been considerably lower than previous waves [2,14].

116 Observational data suggest that vaccines remain effective against Omicron-related

117 hospitalization [15,16].

118 Several reports [11,17-19] have compared the risk of hospitalization or severe disease based on

119 SARS-CoV-2 variant, some suggesting that Omicron is probably less severe than Delta in

120 vaccinated and unvaccinated individuals [11,17,18]. However, a recent preliminary report found

121 no difference in severity between Omicron and Delta [19]. While some studies have stratified

- results by vaccination status [11,17,18] and age [17], none have comprehensively evaluated the
- 123 simultaneous impact of these and other important factors (e.g., chronic medical conditions,
- 124 frailty) on more detailed measures of relative clinical severity in UK hospitalized patients.
- 125
- 126 In this study, we assessed the relative impact of SARS-CoV-2 variant on three separate COVID-
- 127 19-related severity measures in adults hospitalised with SARS-CoV-2 infection, after adjusting
- 128 for important potential confounders, including age, frailty, and vaccination status.

129 **METHODS**

130 Study design and study population

- 131 We are conducting a prospective cohort study of adults hospitalised with acute respiratory illness
- 132 to North Bristol and University Hospitals Bristol and Weston NHS Trusts and now report those
- presenting 1^{st} June 2021 28th March 2022 inclusive. All adults aged ≥ 18 years admitted to these
- hospitals were screened for respiratory disease signs/symptoms [20]. Of these, patients who
- tested positive for COVID-19 (detailed below) were included. Details of the UK COVID-19
- 136 Vaccination Programme are provided in Supplementary Data 1.
- 137

138 **Data Collection**

- 139 Clinical data were collected from electronic and paper patient records and recorded on an
- 140 electronic case report form using REDCap software [21]. Variables collected included: gender;
- 141 age in years; ethnicity; patient pre-existing diseases; vaccination status; age (categorical);
- 142 markers of frailty (Charlson Comorbidity Index [CCI] [22], QCovid2 hazard, [23] Rockwood
- score [24]); immunosuppressive therapy; residence in a care home; index of multiple deprivation
- 144 (IMD); symptom duration prior to admission; hospital site and study week number. We also
- 145 collected data about treatment requirement, including: hospital length of stay (LOS); need for
- supplementary oxygen and level of oxygen provided; requirement for positive pressure
- 147 ventilatory support.

148

149 Data collection was undertaken by individuals not involved in data analysis and collection of 150 data methods were identical for patients with Omicron and Delta variant infections. Vaccination 151 records for each study participant were obtained by team members unaware of subjects' SARS-

152	CoV-2 test results from linked hospital and GP records, including details of vaccination brand
153	and administration date. The QCovid2 hazard score was calculated for each admission [23],
154	estimating risk of hospitalisation or death due to COVID-19 infection. We also determined the
155	CCI score [22,25], with higher scores indicating not only a greater mortality risk but also more
156	severe comorbid conditions, and the Rockwood frailty score[24], a 9-point scale with score ≥ 5
157	indicating frailty.

158

159 Case definitions and exclusions

160 SARS-CoV-2 infection was defined as respiratory disease and a positive test result for SARS-

161 CoV-2 on/during hospitalisation or within 7 days prior to hospital admission, using the

162 established UK Health Security Agency (UKHSA) diagnostic assay deployed at the time.

163 Infection with a particular SARS-CoV-2 variant was likewise determined using the standard

164 UKHSA variant identification methods deployed at the time. Initially, Delta was identified by S-

165 gene positive PCR (SGTP), which was replaced on 11th May 2021 by the P681R target following

166 validation. Omicron was identified as S-gene negative (SGNP) and then by K417N mutation

167 [26]. Cases without variant identification results admitted between the 1st June 2021 and 7th

168 November 2021 were inferred to be Delta, and those after 7th Feb 2022 were inferred to be

169 Omicron. These two dates represent the first date of a proven Omicron admission and the last

170 date of a proven Delta admission in the Bristol area, respectively.

171

172 Patients developing symptoms >10 days prior to hospitalisation were excluded to avoid

173 including individuals who may have falsely tested negative for SARS-CoV-2 upon admission

174 because they presented to hospital late in their clinical course as were individuals who had been

175 inpatients for >28 days prior to their first positive SARS-CoV-2 PCR test. Patients who were 176 partially vaccinated, i.e. had received only one dose or a second dose <7 days before the time of 177 symptom onset, and those who had previously recovered from COVID-19 and had not been 178 vaccinated, were also excluded from the analysis, as their immunological status was uncertain 179 and would prevent meaningful comparison between vaccinated and unvaccinated individuals. 180 Individuals were defined as unvaccinated if they had never received any COVID-19 vaccine. 181 Immunisation with only two vaccine doses was defined as receipt of two doses with \geq 7 days 182 elapsing between symptom onset and the second dose (and no third dose). Immunisation with 183 three doses was defined as receipt of a third vaccine dose after receiving two doses, with \geq 7 days 184 elapsing between the third dose and symptom onset. Only patients being admitted with COVID-185 19 for the first time were included, as repeat admissions may be expected to follow different 186 clinical courses.

187

188 **Outcome and covariates**

189 The primary comparison is between cases infected with SARS-CoV-2 Delta variant and SARS-190 CoV-2 Omicron variant in hospitalised adults. To investigate disease severity and consider the 191 hypothesis that Omicron is associated with less severe outcomes in patients hospitalised with 192 COVID-19, we considered three binary outcomes measured on the seventh day following 193 admission: (1) maximum oxygen requirement FiO₂ >28%, (2) a WHO outcome score greater 194 than 5 (i.e. ventilation or intubation required or death) within the first seven days of 195 hospitalisation (which also implies a maximum oxygen requirement $FiO_2 > 28\%$) [27], and (3) 196 length of stay longer than three days. The WHO outcome score, or clinical progression scale is 197 based on the level of invasive ventilation required and, in admitted patients, scores range from 4

198 to 10 (4 = room air, 5 = oxygen supplementation required, 6 = non-invasive positive pressure199 ventilation [NIPPV] usage, and 7-9 needing endotracheal intubation). A score of 10 represents 200 death. Outcome measures were chosen to reflect different operational concerns for hospitals, in 201 particular the adequacy of oxygen supply, availability of high dependency care, and a measure of 202 overall hospital bed utilisation. We measured the scores at day seven to include relevant data from the hospital admission and to prevent complications with right censoring. Thresholds for 203 204 the outcomes used here were determined empirically following an initial investigation, and a 205 sensitivity analysis conducted on the level of each threshold. Charlson Comorbidity Index and 206 age were divided into categories. For CCI the scores were categorised into none (CCI of 0), mild 207 (1-2), moderate (3-4) or severe (5 or more) and have an approximately even spilt across the data. 208 For age, bands of 18-34 years (y), 35-49y, 50-64y, 65-74y, 75-84y and 85y and over, were 209 chosen as approximately even categories with more resolution in older age groups.

210

211 Statistical Analysis

212 The demographics of patients with Delta and Omicron infection were described using mean \pm 213 standard deviation (SD) or median (interquartile range [IQR]) and compared using Fisher exact 214 tests for categorical variables, two sided Kolmogorov-Smirnov tests for continuous variables and 215 two-sided Wilcoxon-Mann-Whitney tests for score variables. Where categorical data were 216 missing, this comparison was performed with both missing data removed and with missing data 217 included as a separate category (Table 1). There were no missing data items for continuous 218 variables. We examined trends in patients hospitalised over the study period, determining the 219 proportion of hospitalisations with each variant, by vaccination status (unvaccinated, two or three 220 dose of any COVID-19 vaccine) and age group.

221

The complex interaction between the dynamics of UK variant distribution and the progressing age-stratified booster campaign rollout was hypothesised to influence both the risk profile of patients hospitalised and severity of outcome once hospitalised. The outcomes are relatively frequent in both groups which can make interpretation of odds ratios resulting from logistic regression complex [28]. Thus, we used Poisson regression with a robust error variance [28] to estimate the relative risk of each of the three outcomes.

228

229 The primary comparison was the impact of the variant on hospital outcomes. Other covariates 230 were identified that might also influence, with variable distribution by variant provided 231 (Supplementary Table 3). Covariates were screened for systematic biases due to missing data, 232 resulting in removal of IMD (Supplementary Tables 4, 5). Remaining missing data were imputed 233 using the fully conditional specification approach implemented using the `mice` package in R 234 [29]. Multiple imputations were performed, with full analysis repeated for each imputation. The 235 resulting coefficients for each imputation were combined using a mixture distribution, assuming 236 normally distributed beta coefficients. For each factor and outcome, the univariate relative risk 237 was estimated, followed by a multivariable model of a linear combination of genomic variant, 238 vaccination, age and CCI [22]. As a sensitivity analysis these were fully adjusted using the 239 remaining covariates, gender, ethnicity, immunosuppressive therapy, residence in a care home, 240 duration of symptoms prior to admission, hospital site, and study week number. Additional 241 sensitivity analyses were conducted using different combinations of age and frailty markers, 242 including CCI as a continuous variable, Rockwood score [24] and QCovid2 hazard rate (which

- includes age) [23]. Further sensitivity analyses were conducted looking at different thresholdvalues of each of the three binary outcomes.
- 245
- 246 Statistical analyses were performed in R, version 4.0.2 [30]. Robust Poisson regression was
- 247 performed using maximum likelihood estimation of a generalised linear model (positive outcome
- coded as 1, negative outcome as 0). We employed a logarithmic link function, and
- 249 heteroscedasticity consistent covariance matrix estimators. [28,31] Statistical significance was
- defined using a 2-sided significance level of $\alpha = 0.05$. We also conducted sensitivity analysis on
- the statistical model using quasi-Poisson and log-binomial regression giving relative risks and
- 252 logistic regression giving odds ratios.
- 253

254 **Ethics and permissions**

- 255 Approved by the Health Research Authority Research Ethics Committee (East of England,
- Essex), REC 20/EE/0157, including use of Section 251 of the 2006 NHS Act authorised by the
- 257 Confidentiality Advisory Group.

258

259 **Role of the funding source**

260 This study was conducted as a collaboration between the University of Bristol and Pfizer. The

- 261 University of Bristol is the study Sponsor. The funders of the study did not play any part in data
- 262 collection; they collaborated in study design, data analysis and manuscript preparation.

During the study period reported here, 3297 hospital-admissions with SARS-CoV-2 were

263 **RESULTS**

264

265 identified, resulting in 1938 SARS-CoV-2 positive qualifying hospitalisations: 1190 (27 266 inferred) with Delta variant and 748 (119 inferred) with Omicron variant. Overall, 142(76 Delta 267 and 66 Omicron) cases were excluded from analysis due to being partially vaccinated, or with an 268 infection acquired in hospital, or both (Figure 1). 269 270 Patients hospitalised with Omicron variant were statistically significantly older than those with 271 Delta infection (median [IQR]: 70.6 y [44.8y-83.5y] versus 57.7y [42.6y-74.1y] respectively, 272 P < 0.001) and had a higher CCI (4 [1–5] versus 2 [0–4] respectively, P < 0.001). These individuals 273 were also more likely to have received a third vaccination dose (60.2% (N=679) versus 5.0% 274 (N=1114) respectively, P<0.001 (Table 1). Additional analysis investigated the nature of the 275 additional comorbidities (Supplementary Table 1) and vaccination (Supplementary Table 2), 276 showing that patients admitted with Omicron infection were more likely to have pre-existing 277 heart disease, hypertension, atrial fibrillation, dementia, mild chronic kidney disease (CKD), and 278 peripheral vascular disease than patients admitted with Delta infection (all P<0.001). 279 280 The proportion of hospitalisations with the Omicron variant increased over time, with Omicron

becoming the dominant variant in the last week of December 2021 (Figure 2A). As the
vaccination campaign progressed over the study period, we saw an increasing proportion of
hospitalised individuals who had received two vaccine doses or booster (Figure 2B). Hospital
admissions occurring early in the study tended to be younger: the admission age profile shifted
towards older groups with time, with a change point in late December 2021, coincident with

286 increasing Omicron cases (Figure 2C). Overall, the patterns suggest that patients hospitalised 287 between December and February were generally older and frailer, but more commonly 288 vaccinated.

289

290 However, patients hospitalised with Omicron infections experienced less severe outcomes 291 compared to patients infected with Delta. Omicron hospitalisations required ventilation less 292 frequently (Figure 3A), and when they did, a lower oxygen supplement was needed (Figure 3B). 293 The WHO outcome score was also lower within the first seven admission days (Figure 3C). 294

There was no discernible difference in these outcomes between Delta and Omicron in patients

295 \geq 85 years (Figure 3D, 3E). Length of hospital stay was shorter for Omicron compared to Delta

296 among patients <70 years of age but similar for ≥ 70 years (Figure 3F).

297

298 Direct associations such as unadjusted estimates account for neither the changes in patient frailty 299 nor vaccination status observed over the study period (Figure 3). Figure 4 presents results of 300 adjusted regression models that account for these time-varying factors observed over the study 301 duration (methods in Supplementary Tables 3-11, results in Supplementary Tables 12, 13). 302 Relative to Delta, patients infected with Omicron were less likely to require oxygen 303 supplementation of FiO₂ >28% [Relative risk (RR)=0.42 (95%CI: 0.34-0.52)], to have a WHO 304 outcome score >5 (which implies that a patient required positive pressure ventilatory support or 305 died in the hospital) [RR=0.33 (95% CI: 0.21-0.50)], and to have a hospital stay lasting over three 306 days [RR=0.84 (95% CI: 0.76-0.92)]. In stratified analyses by vaccination status, infection with 307 Omicron relative to Delta was associated with lower severity across all three measures in both 308 vaccinated and unvaccinated patients.

309

310	Compared to unvaccinated patients, individuals vaccinated with two doses were less likely to
311	require oxygen >28% FiO ₂ [RR=0.78 (95%CI: 0.68-0.89)], positive pressure ventilatory support
312	or increased critical care [RR= 0.56 (95%CI: $0.43-0.73$)], and to have a hospital admission >3
313	days [RR=0.90 (95%CI: 0.84-0.98)]. Results for vaccination with three doses were similar but
314	had wider confidence intervals than for two doses. In analyses stratified by infecting variant,
315	vaccination was associated with lower severity of disease using all three measures for both
316	Omicron and Delta infections. In analyses assessing potential effect modification by adding an
317	interaction term between variant and vaccination status to adjusted models, the interaction term
318	was not significant for any severity outcome (Supplementary Table 14).
319	
320	In sensitivity analyses using threshold levels of increased severity to dichotomize outcomes, the
321	relative lower severity of Omicron declined further when using higher thresholds for oxygen
322	requirement [FiO ₂ >35%: RR=0.27 (95%CI: 0.19-0.39); FiO ₂ >50%: RR=0.23 (95%CI: 0.15-
323	0.37); Supplementary Table 15]. Sensitivity analysis using a WHO outcome score threshold >6
324	(hence necessitating intubation) had insufficient statistical power (Supplementary Table 16).
325	When longer thresholds for LOS were used, the lower relative severity of Omicron attenuated as
326	the threshold increased [LOS >5 days: RR=0.81 (95%CI: 0.71-0.92); LOS >7 days: RR=0.85
327	(95%CI: 0.73-0.99); Supplementary Table 17], suggesting certain patient characteristics may be
328	associated with shorter admissions. For vaccination, the protective effect of vaccines increased as
329	the severity level threshold increased for each outcome measure. Associations were similar in
330	sensitivity analyses that replaced age group and CCI with the QCovid2 score.
331	

331

332 **DISCUSSION**

333 We found evidence that in adults hospitalised with COVID-19, Omicron infection was 334 associated with less severe illness than that caused by Delta and that vaccination was 335 independently associated with lower in-hospital disease severity using three separate measures of 336 severity. Compared to Delta, Omicron-related hospitalizations were 58%, 67%, and 16% less 337 likely to require high flow oxygen >28% FiO₂, positive pressure ventilatory support or more 338 critical care, and to have a hospital stay lasting more than three days, respectively. These 339 findings persisted even after controlling for multiple potential confounders including age, 340 chronic medical conditions, frailty, and increasing vaccination coverage over time. Our findings 341 are in keeping with previously published assessment of the relative severity of Omicron variant 342 infection compared to other variants, which examined markers of severity such as 343 hospitalization, ICU admission, mechanical ventilation, severe disease and death [32,33] 344 [11,17,18]. Lauring et al. reported lower in-hospital severity for Omicron than for Delta among 345 unvaccinated patients and that vaccinated patients experienced less severe disease regardless of 346 infecting variant[11]. Although studies have reported lower severity for Omicron relative to 347 Delta, measured as the risk of hospitalization [17,18] or death [17] after taking into account 348 vaccination status, the scientific evidence continues to evolve.

349

However, in determining the reduced requirement of increased oxygen requirement and total positive pressure requirement, including non-invasive ventilation, this analysis should contribute to future hospital care and service planning assessments. The impact of lower severity Omicronrelated hospitalization must be balanced with increased transmissibility and overall higher numbers of infections with this variant. Considerable morbidity resulted from Omicron infection,

355 with 18% of Omicron admissions requiring oxygen supplementation $FiO_2 > 28\%$, 6% requiring 356 positive pressure ventilation, 62% needing hospitalization \geq four days, and 4% in-hospital 357 mortality. Despite individual-level risk reduction of needing increasing oxygen supplementation 358 or high dependency care with Omicron compared to earlier variants, healthcare systems could 359 still be overwhelmed by the sheer case numbers and resulting high hospitalization burden, 360 especially if the less severe variant is offset by increasingly frail and elderly patients requiring 361 hospitalization. Omicron's increased transmissibility also increases the infection risk for clinical 362 and other hospital staff, which can take a significant toll on staffing levels. 363 364 The length of hospitalization in individuals who have already developed disease severe enough 365 to merit hospital admission is affected by multiple factors which may confound the effect of any 366 pathogen or strain, including patient frailty and need for continued care following discharge. 367 Other events unrelated to the patient's primary pathology, such as secondary hospital-acquired 368 infection, may also impact discharge. Therefore, discerning the effect of variant on hospital 369 length of admission is difficult. In contrast, the reductions in oxygen requirements and lower 370 WHO outcome scores we observe for Omicron infections are reassuring. This suggests that 371 exhaustion of oxygen supplies or high dependency care beds are less likely in large waves of 372 community Omicron infection than with Delta and other previous variants. Vaccination reduces 373 these risks further and our results suggest it is an important modifier of the impact of these 374 aspects on health services. 375

- 376
- ---
- 377

378 Our study has several strengths. All patients were admitted to hospital with acute respiratory 379 illness caused by SARS-CoV-2, so these results are unlikely to be subject to bias caused by 380 admission for other causes (i.e., incidental COVID-19 disease). In the UK, all national 381 programme vaccines are provided at no cost at the point of delivery; hence our cohort is not 382 biased by issues surrounding the cost of vaccination that are seen in fee-based systems [34]. 383 While week of symptom onset was identified as a significant univariate predictor for adverse 384 outcome, we observe it becomes non-significant on a multivariable analysis which includes time 385 varying factors, such as vaccination, or variant status (Supplementary Tables 6, 8, 10). This 386 reassures us that there are no other time varying factors for which we have not accounted. With a 387 comparatively rich data set of prospectively collected information, we can determine timing of 388 disease onset accurately and capture information on a range of factors more precisely, such as 389 vaccination status and patient comorbidities, than could be done using a retrospective design. 390

391 However, we are limited in this study to observation of patient outcomes in patients only after 392 hospital admission. Thus, we cannot draw conclusions about the severity of Omicron infections 393 occurring entirely in the community. We observed a change in the demographics of patients 394 being admitted towards more elderly and frail populations, which could be explained if 395 community Omicron disease were especially milder in young and healthy individuals. The 396 effects we observed for Omicron and vaccination on clinical outcomes in hospitalised patients 397 occurred over and above any community-level effects. In this study, lineage association was 398 only done using lineage-specific PCRs, and it was not possible to attribute a particular case to an 399 exact sub-lineage. During the period of this analysis the Omicron sub-lineages circulating in the 400 UK were BA.1 and to a small extent BA.2. The Delta sub-lineages were principally

401 undifferentiated B.1.617.2 and AY.4, as shown in Supplementary Figure 1. Estimates presented 402 here are for the combined effect of the sub-lineages. We did not have sufficient data to determine 403 the effectiveness of any individual vaccine against the outcomes studied and our results cannot 404 be interpreted as a vaccine effectiveness estimate. Furthermore, we did not have sufficient 405 statistical power to determine with confidence whether booster doses of COVID-19 vaccine 406 offered additional protection against adverse outcomes. We are unable to control for pressures in 407 the social care system following discharge, and large waves of community Omicron infection 408 may put pressure on community elderly care facilities resulting in a backward pressure on 409 hospital discharges. This could partially explain our observation that length of stay longer than 410 three days is less associated with variant status and vaccination than other outcomes. Although 411 dexamethasone was used as treatment in both Delta and Omicron waves, novel antivirals were 412 introduced throughout the study and this may affect results. Whilst the population of the Bristol 413 area is representative of the UK population, it is principally Caucasian, and our findings must be 414 interpreted in this context. Routine testing for anti-nucleocapsid antibodies was not conducted, 415 and we therefore do not have these data available for determining previous infection status of 416 hospitalised individuals within the Bristol area nor how our findings were impacted by 417 population-level changes in infection-derived or hybrid immunity over time. The study design 418 does not involve any clustering of observations, but we cannot exclude spontaneous formation of 419 clusters in the data set due to outbreaks in the catchment area, which we can only partly mitigate 420 by including covariates of age, CCI and vaccination status.

421

In this prospective study, patients hospitalised with Omicron infections had lower clinicalseverity than those with Delta infections, as assessed by maximal oxygen requirements, a

- validated WHO outcome score, and hospital length of stay. Omicron infection, however, still
 resulted in substantial patient and public health burden following admission. Older and frail
 patients remain particularly susceptible to severe SARS-CoV-2 infection, underscoring the
 importance of maintaining high levels of vaccine coverage in this population. Understanding
 differences in the risk of clinical disease caused by SARS-CoV-2 variants following infection
 and following hospitalisation, and the role of vaccination and other factors in modifying risk, is
 critical for planning of public health measures.
- 431

432 FIGURE LEGENDS

433 Figure 1: Flow diagram of adults hospitalised with SARS-CoV-2 infection

- 434 Inclusion and exclusion criteria in the cohort stratified by the primary comparison or SARS-
- 435 CoV-2 variant. Any patient may be excluded for multiple reasons at each stage, hence the counts
- 436 of reasons for exclusion may not add up to the number of patients excluded.
- 437 FiO₂, fraction of inspired oxygen; LOS, length of stay; VOC, variant of concern; WHO, World
- 438 Health Organisation
- 439

440 Figure 2: Hospitalisations with SARS-CoV-2 infection throughout the study

441 (A) Daily rates of hospitalisations with Delta and Omicron SARS-CoV-2 infection, (B) 14-day

442 rolling proportions of hospitalisations by vaccination status (excluding people partially

443 vaccinated on admission) and (C) 14-day rolling proportions of hospitalisations by age groups

444 (in years) throughout the study. Vertical lines represent the earliest time an Omicron case was

445 admitted and the latest time a Delta case was admitted. Before the earliest Omicron detection,

446 cases are assumed to be Delta when sequencing results are not available, and after the last Delta

447 detection, cases are assumed to be Omicron, when sequencing results are not available.

448

449 Figure 3: The detailed breakdown of the three selected indicators of severity of hospital

450 admission stratified by SARS-CoV-2 variant, and the comparison of three binary

451 indicators of hospital burden and their relationship to SARS-CoV-2 variant and patient

452 age, for patients admitted to hospital.

453	The distribution of patients (A) requiring different peak levels of oxygen supplementation, (B)
454	with different ventilation requirements as defined by the WHO outcome or clinical progression
455	score, and (C) with different lengths of stay. The proportion of patients who (D) require high
456	flow oxygen >28% FiO ₂ , (E) have a WHO outcome score>5 (requiring NIPPV), and (F) have a
457	hospital length of stay greater than three days, as assessed on the seventh day following
458	admission. Error bars show 95% binomial confidence intervals for each outcome, compared to
459	other outcomes.
460	FiO ₂ , Fraction of inspired oxygen; LOS, length of stay; NIPPV, non-invasive positive pressure
461	ventilation
462	
463	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospital
463 464	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospital burden.
463 464 465	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospital burden. Relative risks describing the effect of different predictors on whether patients require oxygen
463 464 465 466	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospitalburden.Relative risks describing the effect of different predictors on whether patients require oxygensupplementation with FiO2 >28% (first column), have a WHO outcome score greater than 5
463 464 465 466 467	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospitalburden.Relative risks describing the effect of different predictors on whether patients require oxygensupplementation with FiO2 >28% (first column), have a WHO outcome score greater than 5(second column) or who remain in hospital for more than 3 days (third column) measured on the
 463 464 465 466 467 468 	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospitalburden.Relative risks describing the effect of different predictors on whether patients require oxygensupplementation with FiO2 >28% (first column), have a WHO outcome score greater than 5(second column) or who remain in hospital for more than 3 days (third column) measured on theseventh day after admission. Numerical details of these regression models, including other
463 464 465 466 467 468 469	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospitalburden.Relative risks describing the effect of different predictors on whether patients require oxygensupplementation with FiO2 >28% (first column), have a WHO outcome score greater than 5(second column) or who remain in hospital for more than 3 days (third column) measured on theseventh day after admission. Numerical details of these regression models, including otherexplanatory variables that are not our primary interest, are given in Supplementary Table 15. A
 463 464 465 466 467 468 469 470 	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospital burden. Relative risks describing the effect of different predictors on whether patients require oxygen supplementation with FiO ₂ >28% (first column), have a WHO outcome score greater than 5 (second column) or who remain in hospital for more than 3 days (third column) measured on the seventh day after admission. Numerical details of these regression models, including other explanatory variables that are not our primary interest, are given in Supplementary Table 15. A comparison of relative risks computed by different methods and odds ratios by logistic
 463 464 465 466 467 468 469 470 471 	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospital burden. Relative risks describing the effect of different predictors on whether patients require oxygen supplementation with FiO ₂ >28% (first column), have a WHO outcome score greater than 5 (second column) or who remain in hospital for more than 3 days (third column) measured on the seventh day after admission. Numerical details of these regression models, including other explanatory variables that are not our primary interest, are given in Supplementary Table 15. A comparison of relative risks computed by different methods and odds ratios by logistic regression is shown in Supplementary Table 18.
 463 464 465 466 467 468 469 470 471 472 	Figure 4: Robust Poisson regression model relative risks for the three indicators of hospitalburden.Relative risks describing the effect of different predictors on whether patients require oxygensupplementation with FiO2 >28% (first column), have a WHO outcome score greater than 5(second column) or who remain in hospital for more than 3 days (third column) measured on theseventh day after admission. Numerical details of these regression models, including otherexplanatory variables that are not our primary interest, are given in Supplementary Table 15. Acomparison of relative risks computed by different methods and odds ratios by logisticregression is shown in Supplementary Table 18.FiO2 – fraction inspired oxygen, LOS – length of stay, CCI – Charlson Comorbidity Index

474 **CONTRIBUTORS**

- 475 CH, RC, RM, LD, JO, JN, JM and AF generated the research questions and analysis plan. CH,
- 476 AM, JK, MC and The Avon CAP team were involved in data collection. CH, RC, RM, LD, and
- 477 AF undertook data analysis. All authors (CH, RC, RM, JN, EB, JS, JK, AM, JK, MC, JO, GE,
- 478 NM, LJ, SG, BG, JMM, LD and AF) were involved in the final manuscript preparation and its
- 479 revisions before publication. AF provided oversight of the research.

480

481 DATA SHARING STATEMENT

- 482 The data used in this study are sensitive and cannot be made publicly available without
- 483 breaching patient confidentiality rules. All analysis code is available on GitHub:
- 484 https://doi.org/10.5281/zenodo.7220569
- 485

486 DECLARATIONS OF INTEREST

487 CH is Principal Investigator of the Avon CAP study which is an investigator-led University of

488 Bristol study funded by Pfizer and has previously received support from the NIHR in an

489 Academic Clinical Fellowship. JO is a Co-Investigator on the Avon CAP Study. AF is a member

490 of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health

491 Organization European Technical Advisory Group of Experts on Immunization (ETAGE)

492 committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he

493 leads another project investigating transmission of respiratory bacteria in families jointly funded

- 494 by Pfizer and the Gates Foundation. LD, RC are members of SPI-M-O subgroups of SAGE and
- 495 are also partly funded through AvonCAP. LD is a Co-Investigator of the AvonCAP study and
- 496 has also received funding from Pfizer, UKRI and UKHSA for unrelated projects. EB, JS, JN,

497 SG, GE, LJ, BG, and JMM are employees of Pfizer, Inc and may hold stock or stock options.

498 The other authors have no relevant conflicts of interest to declare.

499

500 FUNDING

501 This study is a University of Bristol sponsored study which is funded under an investigator-led

502 collaborative agreement by Pfizer Inc. The study funder had no role in data collection, but

503 collaborated in study design, data interpretation and analysis and writing this manuscript. The

504 corresponding author had full access to all data in the study and had final responsibility for the

505 decision to submit for publication.

506

507 ACKNOWLEDGEMENTS

508 The authors would like to thank the UK Health Security Agency (UKHSA) Vaccine

509 Effectiveness Working group and the University of Bristol UNCOVER group for guidance in

510 data analysis and study design. We thank colleagues at the University of Bristol for their support

511 with this study, including Rachel Davies, Paul Savage, Emma Foose, Susan Christie, Mark

512 Mummé, and Adam Taylor. We want to recognise the help from Kevin Sweetland and Aman

513 Kaur-Singh in the AvonCAP study. We would also like to acknowledge the research teams at

514 North Bristol and University Hospitals of Bristol and Weston NHS Trusts for making this study

515 possible, including Helen Lewis-White, Rebecca Smith, Rajeka Lazarus, Mark Lyttle, Kelly

516 Turner, Jane Blazeby, Diana Benton, and David Wynick. We would also like to acknowledge all

517 participants of the many studies undertaken to find effective vaccines against SARS-CoV-2.

518

520 The AvonCAP Research Group:

- 521 Anna Morley, Amelia Langdon, Anabella Turner, Anya Mattocks, Bethany Osborne, Charli
- 522 Grimes, Claire Mitchell, David Adegbite, Emma Bridgeman, Emma Scott, Fiona Perkins,
- 523 Francesca Bayley, Gabriella Ruffino, Gabriella Valentine, Grace Tilzey, James Campling,
- 524 Johanna Kellett Wright, Julia Brzezinska, Julie Cloake, Katarina Milutinovic, Kate Helliker,
- 525 Katie Maughan, Kazminder Fox, Konstantina Minou, Lana Ward, Leah Fleming, Leigh
- 526 Morrison, Lily Smart, Louise Wright, Lucy Grimwood, Maddalena Bellavia, Madeleine Clout,
- 527 Marianne Vasquez, Maria Garcia Gonzalez, Milo Jeenes-Flanagan, Natalie Chang, Niall Grace,
- 528 Nicola Manning, Oliver Griffiths, Pip Croxford, Peter Sequenza, Rajeka Lazarus, Rhian Walters,
- 529 Robin Marlow, Robyn Heath, Rupert Antico, Sandi Nammuni Arachchge, Seevakumar Suppiah,
- 530 Taslima Mona, Tawassal Riaz, Vicki Mackay, Zandile Maseko, Zoe Taylor, Zsolt Friedrich,
- 531 Zsuzsa Szasz-Benczur.

532 **REFERENCES**

- 533 1. Challen R, Dyson L, Overton CE, et al. Early epidemiological signatures of novel SARS-CoV-2 534 variants: establishment of B.1.617.2 in England. *medRxiv* 2021: 2021.06.05.21258365.
- 535 2. Government U. Coronavirus (COVID-19) in the UK. 2022.
- 536 <u>https://coronavirus.data.gov.uk/details/vaccinations?areaType=overview&areaName=United%20Kingdo</u>
 537 m (accessed 14 February 2022).
- 538 3. UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England,
- 539 Technical briefing 36. 2022.
- 540 4. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1.
 541 7. *Nature* 2021; **593**(7857): 130-5.
- 542 5. Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. *New England* 543 *Journal of Medicine* 2021; **384**(15): 1466-8.
- 544 6. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2
 545 Omicron Infection. *New England Journal of Medicine* 2021; **386**(5): 492-4.
- 546 7. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma Neutralization of the SARS-CoV-2 Omicron
 547 Variant. *New England Journal of Medicine* 2021; **386**(6): 599-601.
- 548 8. Ferguson N, Ghani A, Hinsley W, Volz E. Report 50: Hospitalisation risk for Omicron cases in
 549 England. *Imperial College London* 2022.
- 550 9. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron variant of 551 concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative 552 design study in Scotland. *University of Edinburgh* 2021.
- 553 10. UKHSA. COVID-19 vaccine surveillance report: Week 11: UK Government, 2022.
- Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA
 vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States:
 prospective observational study. *BMJ* 2022; **376**: e069761.
- Ferdinands J, Rao S, Dixon B, al e. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines
 Against COVID-19–Associated Emergency Department and Urgent Care Encounters and
- Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance VISION
 Network, 10 States, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**: 255-63.
- 561 13. Thompson M, Natarajan K, SA I, al e. Effectiveness of a Third Dose of mRNA Vaccines Against
- 562 COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among
- Adults During Periods of Delta and Omicron Variant Predominance VISION Network, 10 States,
- 564 August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**: 139-45.
- Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19 in patients admitted
 to hospital during the omicron wave in South Africa: a retrospective observational study. *The Lancet Global Health.*
- 568 15. Kirsebom FCM, Andrews N, Stowe J, et al. COVID-19 vaccine effectiveness against the omicron
 569 (BA.2) variant in England. *Lancet Infect Dis* 2022.
- 570 16. UKHSA UHSA. COVID-19 vaccine surveillance report: week 19. 2022.
- 571 <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/107511</u>
 572 5/COVID-19_vaccine_surveillance_report_12_May_2022_week_19.pdf (accessed 8th June 2022 2022).
- 574 death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a 575 cohort study. *The Lancet*.
- 576 18. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with
- 577 SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis* 2021; **21**(11): 1507-17.
- 579 19. Strasser Z, Hadavand A, Murphy S, Estiri H. SARS-CoV-2 Omicron Variant is as Deadly as
- 580 Previous Waves After Adjusting for Vaccinations, Demographics, and Comorbidities. *Research Square*
- 581 2022.

- 582 20. Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19
- 583 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, 584 case-control study. *The Lancet Infectious Diseases* 2021; **21**(11): 1539-48.
- 585 21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
- capture (REDCap)—A metadata-driven methodology and workflow process for providing translational
 research informatics support. *Journal of Biomedical Informatics* 2009; 42(2): 377-81.
- 588 22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
- 588 22. Charlson ME, Pompel P, Ales KL, MacKenzie CK. A new method of classifying prognostic
 589 comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases* 1987;
 590 40(5): 373-83.
- 591 23. Hippisley-Cox J, Coupland CAC, Mehta N, et al. Risk prediction of covid-19 related death and
 592 hospital admission in adults after covid-19 vaccination: national prospective cohort study. *BMJ* 2021;
 593 374: n2244.
- 594 24. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in
- elderly people. *CMAJ* : *Canadian Medical Association journal = journal de l'Association medicale canadienne* 2005; **173**(5): 489-95.
- 597 25. Physicians RCo. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. *RCP, London* 2017.
- 599 26. UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England, 600 Technical Briefing 33, 2021.
- 601 27. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for 602 COVID-19 clinical research. *Lancet Infect Dis* 2020; **20**(8): e192-e7.
- 28. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004; **159**(7): 702-6.
- van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in
 R. *Journal of Statistical Software* 2011; 45(3): 1 67.
- Team RC. R: A language and environment for statistical computing. . In: Computing RFfS,
 editor. Vienna, Austria; 2014.
- 31. Zeileis A, Köll S, Graham N. Various Versatile Variances: An Object-Oriented Implementation
 of Clustered Covariances in R. *Journal of Statistical Software* 2020; 95(1): 1 36.
- 611 32. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated
- 612 with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in 613 southern California. *Nature Medicine* 2022.
- 614 33. Van Goethem N, Chung PY, Meurisse M, et al. Clinical Severity of SARS-CoV-2 Omicron
- 615 Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and 616 Winter Season 2021–2022. *Viruses* 2022; **14**(6).
- 617 34. Wheelock A, Miraldo M, Thomson A, Vincent C, Sevdalis N. Evaluating the importance of
- 618 policy amenable factors in explaining influenza vaccination: a cross-sectional multinational study. BMJ
- 619 *Open* 2017; **7**(7): e014668.
- 620





+++ indicates p-value < 0.001, ++ p-value < 0.01 and + p-value < 0.05. 'ns' have p-value ≥ 0.05



